{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:20:53Z","timestamp":1790796053526,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.thromres.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T12:19:06Z","timestamp":1375964346000},"page":"341-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease"],"prefix":"10.1016","volume":"132","author":[{"given":"Payal C.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Dominik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie V.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-199104000-00018","article-title":"Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion","volume":"2","author":"Francis","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.thromres.2013.08.002_bb0015","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2013.08.002_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia","volume":"129","author":"Wun","year":"1997","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1016\/j.thromres.2013.08.002_bb0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1067\/mlc.2001.115450","article-title":"Thrombogenesis in sickle cell disease","volume":"137","author":"Tomer","year":"2001","journal-title":"J Lab Clin Med"},{"issue":"7","key":"10.1016\/j.thromres.2013.08.002_bb0030","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/01.ATV.0000220374.00602.a2","article-title":"Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia Potential Role for Platelet-Mediated Inflammation","volume":"26","author":"Lee","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0035","doi-asserted-by":"crossref","first-page":"e29786","DOI":"10.1371\/journal.pone.0029786","article-title":"Association of coagulation activation with clinical complications in sickle cell disease","volume":"7","author":"Ataga","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.thromres.2013.08.002_bb0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1357-2725(00)00016-9","article-title":"CD154 (CD40 ligand)","volume":"32","author":"Schonbeck","year":"2000","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Schonbeck","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.thromres.2013.08.002_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60865-2","article-title":"CD40-CD40 ligand: a multifunctional receptor-ligand pair","volume":"61","author":"Van Kooten","year":"1996","journal-title":"Adv Immunol"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"6667","key":"10.1016\/j.thromres.2013.08.002_bb0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.thromres.2013.08.002_bb0065","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2003.12.055","article-title":"Release of soluble CD40L from platelets is regulated by glycoprotein IIb\/IIIa and actin polymerization","volume":"43","author":"Furman","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.thromres.2013.08.002_bb0070","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2165\/00003495-200565140-00007","article-title":"Eptifibatide: a review of its use in patients with acute coronary syndromes and\/or undergoing percutaneous coronary intervention","volume":"65","author":"Curran","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9149(99)00235-0","article-title":"Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects","volume":"84","author":"Holmes","year":"1999","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.thromres.2013.08.002_bb0080","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","article-title":"Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates","volume":"41","author":"Moser","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"10.1016\/j.thromres.2013.08.002_bb0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/01.CIR.0000053559.46158.AD","article-title":"Inhibitory effects of glycoprotein IIb\/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation","volume":"107","author":"Nannizzi-Alaimo","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ccd.10763","article-title":"GP IIb\/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention","volume":"61","author":"Welt","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.thromres.2013.08.002_bb0095","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0002-9149(03)00327-8","article-title":"Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting","volume":"91","author":"Aggarwal","year":"2003","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.thromres.2013.08.002_bb0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/hc3101.092199","article-title":"Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin","volume":"104","author":"Lele","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.thromres.2013.08.002_bb0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1161\/01.CIR.0000081774.31064.62","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease","volume":"108","author":"Heitzer","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2013.08.002_bb0110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.2007.06787.x","article-title":"Phase I study of eptifibatide in patients with sickle cell anaemia","volume":"139","author":"Lee","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.thromres.2013.08.002_bb0115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.thromres.2013.08.002_bb0120","series-title":"Up To Speed With Categorical Data Analysis","author":"Stokes","year":"2011"},{"key":"10.1016\/j.thromres.2013.08.002_bb0125","first-page":"642","article-title":"Hodges-Lehmann Estimators","volume":"3","author":"Hodges","year":"1983"},{"issue":"9","key":"10.1016\/j.thromres.2013.08.002_bb0130","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1553-2712.2004.tb00791.x","article-title":"The effect of magnesium on length of stay for pediatric sickle cell pain crisis","volume":"11","author":"Brousseau","year":"2008","journal-title":"Acad Emerg Med"},{"issue":"9","key":"10.1016\/j.thromres.2013.08.002_bb0135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jama.2011.235","article-title":"Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis A Randomized Controlled Trial","volume":"305","author":"Gladwin","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.thromres.2013.08.002_bb0140","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199403173301101","article-title":"High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease","volume":"330","author":"Griffin","year":"1994","journal-title":"N Eng J Med"},{"issue":"17","key":"10.1016\/j.thromres.2013.08.002_bb0145","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease","volume":"286","author":"Orringer","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.thromres.2013.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.289.9.1136","article-title":"Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease","volume":"289","author":"Weiner","year":"2003","journal-title":"JAMA"},{"issue":"9247","key":"10.1016\/j.thromres.2013.08.002_bb0160","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"The ESPRIT Investigators","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/09537100802592676","article-title":"Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction","volume":"20","author":"Attaya","year":"2009","journal-title":"Platelets"},{"issue":"6","key":"10.1016\/j.thromres.2013.08.002_bb0170","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/SMJ.0b013e3181de0cca","article-title":"Acute Profound Thrombocytopenia Following Eptifibatide Administration","volume":"103","author":"Tahir","year":"2010","journal-title":"South Med J"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0175","first-page":"86","article-title":"Eptifibatide-Induced Thrombocytopenia: with Thrombosis and Disseminated Intravascular Coagulation Immediately after Left Main Coronary Artery Percutaneous Coronary Angioplasty","volume":"39","author":"Tempelhof","year":"2012","journal-title":"Tex Heart Inst J"},{"issue":"9063","key":"10.1016\/j.thromres.2013.08.002_bb0180","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"The IMPACT-II Investigators","year":"1997","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.thromres.2013.08.002_bb0185","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of Platelet Glycoprotein IIb\/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes","volume":"339","author":"The PURSUIT Investigators","year":"1998","journal-title":"N Eng J Med"},{"issue":"3","key":"10.1016\/j.thromres.2013.08.002_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.thromres.2005.07.020","article-title":"Increased expression of platelet P-selectin and formation of platelet\u2013leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin","volume":"118","author":"Keating","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.08.002_bb0195","first-page":"199","article-title":"Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents Actions Suppl"},{"issue":"3","key":"10.1016\/j.thromres.2013.08.002_bb0200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-0038-1650055","article-title":"Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises","volume":"43","author":"Chaplin","year":"1980","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.thromres.2013.08.002_bb0205","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3476(83)80258-3","article-title":"Trial of low doses of aspirin as prophylaxis insickle cell disease","volume":"102","author":"Greenberg","year":"1983","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.thromres.2013.08.002_bb0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.thromres.2013.08.002_bb0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases with aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.thromres.2013.08.002_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-6-17","article-title":"A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease","volume":"6","author":"Wun","year":"2013","journal-title":"J Hematol Oncol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T13:51:19Z","timestamp":1596289879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813003319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0049384813003319"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718086446.793510073","asserted-by":"object"}]},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}